Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCERTAIN: Everolimus with CNI Reduction in Renal Transplant
NCT00170846Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in kidney transplant rejection and Chronic Allograft Kidney Disease (CKaD) (3 arms), sponsored by Novartis. Primary endpoint: Renal Function Assessed by Measured GFR at 24 months. Started Feb 2005; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant rejectionChronic Allograft Kidney Disease (CKaD)
Beyond the preview
Go deeper on NCT00170846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170846.